The tweet was deleted by the author.
But we saved everything 🙂.
Upstream Bio announces pivotal Phase 3 plans for verekutug while stock edges lower
Upstream Bio announced plans for pivotal Phase 3 trials of verekutug in severe asthma and chronic rhinosinusitis with nasal polyps, with studies slated to begin in 2027 targeting an expanded patient population. Shares edge lower on the day, trading at $6.62.
Highlights
- Upstream Bio will begin Phase 3 trials for verekutug in severe asthma and chronic rhinosinusitis with nasal polyps in 2027 targeting a $35 billion market opportunity.
- Shares of Upstream Bio edge lower on the day, trading at $6.62.
- 28 of 34 analysts rate Upstream Bio stock a buy, with the median price target at $30.5.
Upstream Bio announced pivotal plans for Phase 3 development of verekutug in severe asthma and chronic rhinosinusitis with nasal polyps. According to the company, it will study a 400mg quarterly dose in one pivotal trial for each condition, after completing End-of-Phase 2 meetings with the FDA. Phase 3 trials are planned for 2027 and will target a global market opportunity estimated at over $35 billion, TradingView reported.
View post on X Loading...
Broad intraday swings as index levels cap rebound risk
Shares of Upstream Bio moved within an unusually wide intraday range in the latest session, touching a low of $6.44 and a high of $6.77, compared to the weekly average. The price remains below its MA-20, MA-50, and MA-200, maintaining the daily chart's bearish structure. Stoch RSI is sitting in oversold territory, which limits the potential for additional downside from these levels.
Outlook skews bearish as downside odds dominate the weekly setup
Traders should watch whether the price closes above $6.9 or falls below $6.44 to gauge follow-through or rejection. In the latest session, the stock traded between $6.44 and $6.77, with a range that exceeded the week's typical movement. Still, even after a sharp move lower over the past week without a sustained trend, the outlook for the coming trading week shows less than 20% probability of upside and more than 80% chance of downside, with an expected range of $6.23 to $7. A close above $6.9 would indicate buyers are willing to carry the move higher, while a break below $6.44 would suggest recent gains are being faded. On the weekly chart the longer-term picture stays firmly negative.
Previously it was reported that Upstream Bio would initiate two pivotal Phase 3 trials of verekutug in severe asthma and chronic rhinosinusitis with nasal polyps following regulatory discussions. The current article confirms these plans and highlights that, with shares maintaining a bearish technical structure, monitoring a break below $6.44 remains key for downside risk in the coming week.
This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Subscribe to TU news
Did you like the article?
Top News
Top 5 companies for you
United States
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
Live News
